LU85616A1 - Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci - Google Patents

Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci Download PDF

Info

Publication number
LU85616A1
LU85616A1 LU85616A LU85616A LU85616A1 LU 85616 A1 LU85616 A1 LU 85616A1 LU 85616 A LU85616 A LU 85616A LU 85616 A LU85616 A LU 85616A LU 85616 A1 LU85616 A1 LU 85616A1
Authority
LU
Luxembourg
Prior art keywords
prazosin hydrochloride
anhydrous
crystalline form
stable
chosen
Prior art date
Application number
LU85616A
Other languages
English (en)
French (fr)
Inventor
Stig Olof Engelbert Lindholm
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of LU85616A1 publication Critical patent/LU85616A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU85616A 1984-06-25 1984-10-29 Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci LU85616A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI842544 1984-06-25
FI842544A FI79107C (fi) 1984-06-25 1984-06-25 Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.

Publications (1)

Publication Number Publication Date
LU85616A1 true LU85616A1 (fr) 1985-06-04

Family

ID=8519293

Family Applications (1)

Application Number Title Priority Date Filing Date
LU85616A LU85616A1 (fr) 1984-06-25 1984-10-29 Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci

Country Status (17)

Country Link
US (2) US4739055A (cs)
JP (1) JPS6115881A (cs)
AT (1) AT389117B (cs)
AU (1) AU566814B2 (cs)
BE (1) BE900925A (cs)
CH (1) CH661045A5 (cs)
DE (1) DE3429415A1 (cs)
FI (1) FI79107C (cs)
FR (1) FR2567124B1 (cs)
GB (1) GB2160861B (cs)
IL (1) IL73267A (cs)
IT (1) IT1224142B (cs)
LU (1) LU85616A1 (cs)
NL (1) NL8403250A (cs)
NZ (1) NZ209962A (cs)
PT (1) PT79411B (cs)
ZA (1) ZA85910B (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237608A1 (de) * 1986-03-21 1987-09-23 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2756846B2 (ja) * 1989-12-28 1998-05-25 住化ファインケム株式会社 無水のε型結晶体2―〔4―(2―フロイル)ピペラジン―1―イル〕―4―アミノ―6,7―ジメトキシキナゾリン塩酸塩及びその製造方法
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5769966B2 (ja) * 2007-08-17 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Fab関連疾患治療用プリン誘導体
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
WO2010018217A2 (en) * 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE156532C (cs) *
US2969375A (en) * 1961-01-24 Certification of correction
BE427505A (cs) * 1937-05-25
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives
US3433788A (en) * 1966-04-27 1969-03-18 Union Carbide Corp Process for recovery of amines from aqueous solutions by solvent treatment and distillation
US3421983A (en) * 1967-03-07 1969-01-14 Lummus Co Azeotropic distillation of aqueous toluene diamine
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3743672A (en) * 1970-05-27 1973-07-03 Halcon International Inc Separation of water in alkylene glycol mono and diester purification by azeotropic distillation
GB1308718A (en) * 1970-07-01 1973-03-07 Sir Soc Italiana Resine Spa Method of separating vinyl acetate from liquid mixtures
IT956765B (it) * 1972-06-22 1973-10-10 Montedison Spa Procedimento per la purificazione di 1 3 diossolano
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
FI64367C (fi) * 1980-02-26 1986-08-05 Orion Yhtymae Oy Foerfarande foer framstaellning av alfa-form av prazosinhydroklorid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237608A1 (de) * 1986-03-21 1987-09-23 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
DE3429415A1 (de) 1986-01-02
AU3451084A (en) 1986-01-02
IL73267A (en) 1988-06-30
JPS6115881A (ja) 1986-01-23
IL73267A0 (en) 1985-01-31
GB2160861A (en) 1986-01-02
PT79411A (en) 1984-11-01
FI79107B (fi) 1989-07-31
NL8403250A (nl) 1986-01-16
US4873330A (en) 1989-10-10
ZA85910B (en) 1985-09-25
ATA344184A (de) 1989-03-15
FR2567124A1 (fr) 1986-01-10
DE3429415C2 (cs) 1990-05-03
JPH0481993B2 (cs) 1992-12-25
GB8424999D0 (en) 1984-11-07
FI79107C (fi) 1989-11-10
NZ209962A (en) 1987-06-30
GB2160861B (en) 1987-11-18
FI842544A0 (fi) 1984-06-25
AT389117B (de) 1989-10-25
AU566814B2 (en) 1987-10-29
US4739055A (en) 1988-04-19
FR2567124B1 (fr) 1990-09-21
FI842544L (fi) 1985-12-26
PT79411B (en) 1986-09-15
BE900925A (fr) 1985-02-15
CH661045A5 (de) 1987-06-30
IT1224142B (it) 1990-09-26
IT8423292A0 (it) 1984-10-24

Similar Documents

Publication Publication Date Title
LU85616A1 (fr) Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci
EP0210084B1 (fr) Amides, procédés pour leur préparation et médicaments les contenant
EP0576350B1 (fr) Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
KR0173307B1 (ko) 1-페닐-이미다졸린-2,5-디온 유도체의 신규 제조 방법
EP2185543B1 (fr) Procede de dedoublement optique de sels de l'omeprazole
EP1403266B1 (fr) Nouveau procédé de synthèse industriel du ranélate de strontium et de ses hydrates
FR2663934A1 (fr) Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
WO2012010788A1 (fr) Procede de preparation de derives d'amino-benzoyl-benzofurane
EP0382634A1 (fr) Nouveaux dérivés de la pyridazine, procédé de préparation et compositions pharmaceutiques en contenant
EP0309324A1 (fr) Procédé de synthèse d'alpha amino N alkyles et de leurs esters. Application à la synthèse de carboxyalkyl dipeptides
EP0612716B1 (fr) Procédé pour la préparation d'un aminoalcool optiquement pur
FR2793490A1 (fr) Procede de preparation du (1r,2s,4r)-(-)-2-[(2'-{n,n- dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]- bicyclo[2.2.1]-heptane et ses sels d'addition d'acide pharmaceutiquement acceptables
FR2689889A1 (fr) Nouveaux dérivés de perhydroisoindole, et leur préparation.
EP0708759A1 (fr) Procede pour la preparation de pyrazines substituees
EP0240398A1 (fr) Dérivés dissymétriques de l'acide 1,4-dihydropyridine-3,5-dicarboxylique, procédés de préparation et utilisation en thérapeutique
FR2615188A1 (fr) Derives d'hydrazine, procede d'obtention et compositions pharmaceutiques les contenant
CH594650A5 (en) Antiinflammatory (1,2)-benzothiazine derivs. prepn.
CA1129886A (fr) Procede de preparation de n-alcoylamino benzophenones
FR2565972A1 (fr) Preparation des derives d'amines
JP4664903B2 (ja) 4,10β−ジアセトキシ−2α−ベンゾイルオキシ−5β,20−エポキシ−1,13α−ジヒドロキシ−9−オキソ−19−ノルシクロプロパ[g]タキサ−11−エンの製造方法
EP1214309B8 (fr) Preparation d'amidines derivees de l'acide 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylique
EP0003456A1 (fr) Dérivés d'amino-3-cardénolides, procédé pour leur préparation, et médicaments les contenant
JPH0520427B2 (cs)
FR2667065A1 (fr) Procede pour preparer la 1-[(2s)-3-mercapto-2-methyl-1-oxopropyl]-l-proline.
FR2845993A1 (fr) Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques